Tratamento do mieloma múltiplo com VMCP: revisão de 52 casos

• Autor(a) principal: Pinto, Carlos Frederico Distéfano
• Data de Publicação: 2023
• Outros Autores: Silva, Alexandre J. Fenelon, Moreira, Wagner Brant, Cabral Filho, Sebastião, Nascimento, Eduardo, Lopes, Eugênio B., Brandão, Eduardo C., Teixeira, João Augusto M., Vieira, Maria do Carmo, Alvares, Maria N., Novaes, Nedda Maria V.
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3005
• topic: Mieloma Múltiplo; Poliquimioterapia; Fatores Prognósticos; Multiple Myeloma; Chemotherapy; Prognostic Factors

Fifty-two patients were treated for multiple myeloma between November 1987andAugust 1992 at the Santa Casa de Misericórdia de Belo Horizonte General Hospital with VMCP (vincristine, melphalan, cyclophosphamide and prednisone) every28 days. Twenty-six patients with bone lesions received palliative radiotherapy. Fifteen (28.8%) were stage IIIA; 32 (61.5%) stage IIIB; five (7.6%) stage I and II by the Salmon and Durie staging system, as used by the SWOG. The response criteria used, when available, was also the proposed by SWOG. Seven patients reached the complete remission, 12 partial remission, 20had stable disease and 13 had progressiva disease. The overall survival was 41 months. Toxicity was well tolerated in the majority of the group. Grade 3-4 toxicity was reached at least once in 30.8%. Three patients died of neutropenic sepsis and 1 of gastrointestinal toxicity. Eight patients are lost of follow-up. The authors considered the actual regimen safe and with satisfactory results.